JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
| Event: | H.C. Wainwright 3rd Annual BioConnect Investor Conference |
| Format: | Fireside Chat |
| Date: | May 20, 2025 |
| Time: | 3:30 – 4:00PM ET |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2025 Investor Conference |
| Format: | 1x1 Meetings |
| Date: | May 29, 2025 |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.89 |
| Daily Change: | -0.11 -3.67 |
| Daily Volume: | 48,666 |
| Market Cap: | US$202.590M |
May 19, 2025 April 28, 2025 April 02, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
